Photo: supplied
People living with the debilitating respiratory condition cystic fibrosis want Pharmac to fund a breakthrough new drug treatment for a group of 30 patients.
NZ is the only country in the OECD which doesn't publicly fund the drug Kalydeco, which effectively eliminates the effects of the disease for those with a particular strand of cystic fibrosis, but which costs more than 300 thousand per year per patient.
The company which makes the drug - Vertex - has made a submission to PHARMAC's newly established rare diseases sub committee which is currently considering it along with 12 other applications.
